Celltrion, a vaccine development company, announced on the 17th that it has completed the domestic patent registration decision regarding NK cells applied to the BVAC pipeline, an anticancer immunotherapy vaccine being developed.
This patent is for a vaccine technology that includes a natural killer T cell ligand and NK (natural killer) cells loaded with cancer antigens from the CeliVax platform under development by Cellid. The patent has been applied for in Korea and PCT, and is currently under examination in each country.
Through this patent registration, Cellid has secured exclusive rights and protected the core technology of the Cellivax platform. Cellid had individual patents for the Cellivax platform technology using B cells and monocytes, and through this NK cell-related patent registration, the scope of protection for the technology has been further expanded and the exclusive rights have been extended in the long term.
Celltrion is developing a pipeline of six anticancer immunotherapy vaccines using the Cellivax platform technology, and is currently focusing on BVAC-C for cervical cancer and BVAC-E6E7 for head and neck cancer. BVAC-C is undergoing a combination administration investigator-led clinical trial, and announced the results of an interim analysis of efficacy at the 2024 American Society of Clinical Oncology (ASCO), a global cancer conference, on June 1 last year, and plans to verbally present the latest clinical results, which are being continuously observed and analyzed, at the American Society of Gynecologic Oncology (SGO) in March this year. In addition, BVAC-E6E7 received IND approval for a phase 1/2a clinical trial on November 19 last year and is currently in the process of recruiting subjects.
Kang Chang-yool, CEO of CeliVax, said, “This patent registration is the result of official recognition of CeliVax’s research and development capabilities,” adding, “We are working to complete the phase 3 clinical trial of the COVID-19 vaccine and secure data for approval through our unrivaled technological prowess, and we will further strengthen our technological edge in domestic and overseas markets by diversifying our BVAC pipeline.”
- See more related articles
You must be logged in to post a comment.